Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

SYSTEMIC LUPUS ERYTHEMATOSUS

Redefining systemic lupus erythematosus — SMAARTT proteomics

As the diagnosis and management of systemic lupus erythematosus (SLE) can be challenging, reclassification of SLE on the basis of biomarker data provides novel insights. Definitions of antinuclear antibodies and attention to SMAARTT criteria (specificity – sensitivity, measurable, actionable, added value, realistic, titres, timely) are needed to translate these new analytical frameworks into real-time clinical use.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tsokos, G. C., Lo, M. S., Costa, R. P. & Sullivan, K. E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 12, 716–730 (2016).

    Article  PubMed  CAS  Google Scholar 

  2. Pisetsky, D. S., Rovin, B. H. & Lipsky, P. E. Biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus: the example of ANA and anti-DNA. Arthritis Rheumatol. 69, 487–493 (2017).

    Article  PubMed  Google Scholar 

  3. Artim-Esen, B. et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J. Rheumatol. 41, 1304–1310 (2014).

    Article  PubMed  Google Scholar 

  4. To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 52, 4003–4010 (2005).

    Article  PubMed  CAS  Google Scholar 

  5. Pacheco, Y. et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J. Transl Med. 15, 239–1345 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lewis, M. J. et al. Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. J Autoimmun. https://doi.org/10.1016/j.jaut.2018.02.009 (2018).

    Article  Google Scholar 

  7. Pisetsky, D. S. Antinuclear antibody testing - misunderstood or misbegotten? Nat. Rev. Rheumatol. 13, 495–502 (2017).

    Article  PubMed  CAS  Google Scholar 

  8. Mahler, M. Lack of standardisation of ANA and implications for drug development and precision medicine. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213374 (2018).

    Article  Google Scholar 

  9. Barturen, G., Beretta, L., Cervera, R., Van, V. R. & Alarcon-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75–93 (2018).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marvin J. Fritzler.

Ethics declarations

Competing interests

M.M. is employed at Inova Diagnostics manufacturing and selling autoantibody assays. M.J.F. is a consultant to and/or has received research gifts in kind from Alexion Canada, Euroimmun GmbH and Inova Diagnostics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fritzler, M.J., Mahler, M. Redefining systemic lupus erythematosus — SMAARTT proteomics. Nat Rev Rheumatol 14, 451–452 (2018). https://doi.org/10.1038/s41584-018-0035-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-018-0035-3

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research